Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Ruxolitinib as a Treatment of Anti-PD1 Induced Lichenoid Skin Toxicities: a Prospective Single-center Pilot Study

NCT06399029 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT06399029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Ruxolitinib as a Treatment of Anti-PD1 Induced Lichenoid Skin Toxicities: a Prospective Single-center Pilot Study
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 10, 2024
Completion date
May 31, 2026
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

exanthema, lichenoid skin rashes under anti-pd1 tumor therapy